Clinical Study

Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection

Table 1

Baseline clinical characteristics of 144 patients received nucleos(t)de analogues with chronic HBV-infected liver disease at the time of enrollment.

Median (range) value
ADV group ( )Non-ADV group ( )

At the time of enrollment
 Age (yr)52 (29–78)55 (28–83)0.8368
 Sex (male/female)15/582/420.5974
 HBV genotype (A/B/C/F/n.d)2/2/12/1/33/26/65/0/300.8671
 HBV DNA (log10 copies/mL)2.1 > (negative–3.0)2.1 > (negative–6.2)0.1896
 Platelet count (×103/m3)16.5 (10.2–31.0)16.8 (3.4–31.5)0.1987
 ALT (IU/L)26 (10–60)20 (8–124)0.1117
 Alb (g/dL)4.4 (4–5.3)4.4 (1.8–5.2)0.9154
 Cirrhosis (presence/absence)5/1530/940.8392
At the time of starting ADV or ETV
 Serum creatinine (mg/dL)0.8 (0.6–1.2)0.76 (0.52–1.30)0.3853
Follow-up duration (month)103 (37–141)40 (12–152)
Duration of nucleos(t)ide analogue therapy (month)103 (37–141)34 (12–117)
Duration of adefovir administration (month)73 (12–107)
Propensity score0.197 (0.068–0.553)0.108 ( –0.514)0.0018

ADV: adefovir dipivoxil; non-ADV: lamivudine or entecavir.